RxDoctor Payments DataLook up a doctor →

Isha Gupta, MD

Nephrology · Middletown, NYNPI 1922345008

Payments from drug & device makers

$238,361in general payments, 2019–2025

Across 457 payments — averaging $521.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$134K
  • AstraZeneca$54K
  • Novo Nordisk$33K
  • BD$10K
  • Mallinckrodt Hospital Products Inc.$836
  • Bayer$690
  • plus $5K from 41 others

What the payments were for

  • Speaking & faculty fees$25,88162%
  • Travel & lodging$6,30915%
  • Food & beverage$8,26720%
  • Education$1,1593%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$238,361 in reported general payments places this provider in the 95th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$827,275
Medicare patients
744
Services billed
23,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ActharCorticotropin12$1,038,722
FarxigaDapagliflozin Propanediol410$462,283
KerendiaFinerenone239$314,760
OzempicSemaglutide93$103,161
RayaldeeCalcifediol40$72,318
VeltassaPatiromer Calcium Sorbitex39$53,279
JardianceEmpagliflozin37$46,463
RybelsusSemaglutide25$40,695
LokelmaSodium Zirconium Cyclosilicate24$24,013
EliquisApixaban15$20,714
DapagliflozinDapagliflozin Propanediol30$18,431
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$13,486
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,850
Sevelamer Carbonate41$10,014
Losartan Potassium216$1,975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Mallinckrodt Hospital Products Inc.Acthar$836$1,038,72212 claims
AstraZenecaFarxiga, Lokelma, Breztri Aerosphere$54,037$499,782451 claims
BayerKerendia$690$314,760239 claims
Novo NordiskOzempic, Rybelsus$33,282$143,856118 claims
OPKO Pharmaceuticals, LLCRayaldee$631$72,31840 claims
Boehringer IngelheimJardiance$36$46,46337 claims
PfizerEliquis$161$20,71415 claims
GSKTrelegy Ellipta$535$12,85015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 935 nephrology providers in New York.

Other nephrology in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →